Skip to content

Mechanism of human telomerase reverse transcriptase (hTERT) mitochondrial translocation in chemotherapy resistance in hepatocellular carcinoma

Mechanism of human telomerase reverse transcriptase (hTERT) mitochondrial translocation in chemotherapy resistance in hepatocellular carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300070511
Enrollment
Unknown
Registered
2023-04-14
Start date
2023-05-01
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Mitochondrial hTERT high expression group 1:N/A
Mitochondrial hTERT low expression group 1:N/A
Mitochondrial hTERT high expression group 2:N/A
Mitochondrial hTERT low expression group 2:N/A

Sponsors

The Second Affiliated Hospital of Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: All patients meet the following requirements: ? The age ranged from 20 to 80 years, male or female. ? they have received the ultrasound-guided liver biopsy and the biopsy samples has been diagnosed as hepatocellular carcinoma. ? they have received the TACE therapy. ? They have taken CT/MRI examinations before and after the TACE therapy.

Exclusion criteria

Exclusion criteria: ? Non-primary hepatocellular carcinoma; ? Those who have been diagnosed with severe cardiovascular disease, diabetes and other diseases; ? Pregnant women and lactating women.

Design outcomes

Primary

MeasureTime frame
PDX model tumor size;Total hTERT content in tumor tissues;Mitochondrial hTERT content in tumor tissues;

Countries

China

Contacts

Public ContactYang Shiming

The Second Affiliated Hospital of Army Medical University

Yangshiming@tmmu.edu.cn+86 23 68755604

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026